Jan. 26, 2024 – CellMax Life, a molecular diagnostics company with proprietary technology for pre-cancer and cancer detection blood tests, presented the latest results from its independent external validation study on January 20, 2024 at the ASCO Gastrointestinal Cancers Symposium. Data from this external validation study showed that FirstSight™ was able to detect CRC with 92% sensitivity and advanced adenomas (AA) with a 53% sensitivity, increasing to 66% for adenomas with high-grade dysplasia and 69% for large adenomas ≥3cm in size. These results demonstrate best-in-class performance and increase in significance when compared to stool tests and first-generation liquid biopsy tests.

CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer (CRC) screening blood test, that also detects pre-cancerous polyps, or adenomas, today announced the appointment of Dr. Ross D. Segan as an advisory board member.

Feb 21, 2023 – Renowned industry experts support the company as it prepares for premarket approval studies

Feb 21, 2023 – Renowned industry experts support the company as it prepares for premarket approval studies

SUNNYVALE, CA; January 18, 2023 – CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced positive results from a multisite U.S. study that showed that its FirstSight blood test is highly accurate in detecting colorectal cancer, as well as advanced adenomas.